{"gene":"CRLF2","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":2001,"finding":"CRLF2 (cytokine receptor-like factor 2) was cloned as a novel type I cytokine receptor with an extracellular domain containing two fibronectin type III-like domains, four conserved cysteine residues, a WSXWS box-like motif, and an intracellular domain with box 1 and box 2-like motifs, mapping to the pseudoautosomal region Xp22.3/Yp11.3.","method":"cDNA library screening, Northern blot, FISH mapping","journal":"Cytogenetics and cell genetics","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper with multiple orthogonal methods establishing domain architecture and chromosomal location","pmids":["11474172"],"is_preprint":false},{"year":2001,"finding":"CRLF2 (CRL2) is preferentially expressed on dendritic cells and activated monocytes, with expression upregulated by LPS stimulation; the intracellular domain contains a membrane-proximal box 1 motif and a conserved tyrosine residue as a potential binding site for signal transducing molecules.","method":"RT-PCR, Northern blot, immunoprecipitation of FLAG-tagged CRL2 in Ba/F3 transfectants","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — protein expression confirmed by immunoprecipitation, cell-type preference established by RT-PCR","pmids":["11237741"],"is_preprint":false},{"year":2002,"finding":"TSLPR (CRLF2) forms a heterodimeric complex with the IL-7 receptor alpha chain to constitute the functional receptor for TSLP; the WSXWX motif in the extracellular domain is conserved across rat, mouse, and human TSLPR.","method":"cDNA cloning, sequence analysis, genomic structure characterization, zooblot analysis","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1-2 — receptor complex composition established by cloning and functional characterization; replicated across species","pmids":["11891057"],"is_preprint":false},{"year":2009,"finding":"Interstitial deletion of the pseudoautosomal region 1 creates a P2RY8-CRLF2 fusion that juxtaposes the P2RY8 promoter with the CRLF2 coding region, causing CRLF2 overexpression; co-expression of P2RY8-CRLF2 with mutant mouse Jak2 results in constitutive JAK-STAT activation and cytokine-independent growth of Ba/F3 cells overexpressing IL-7Rα.","method":"Genomic deletion analysis, Ba/F3 cell transformation assay, JAK-STAT signaling assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — functional transformation assay with signaling readout; founding mechanistic paper with 458 citations","pmids":["19838194"],"is_preprint":false},{"year":2009,"finding":"CRLF2 overexpression driven by IGH translocation or P2RY8-CRLF2 deletion activates the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining proliferation; CRLF2 deregulation cooperates with JAK2 pseudokinase domain mutations for oncogenic transformation.","method":"Flow cytometry-based proliferation assay, JAK-STAT pathway analysis, primary B-cell progenitor transduction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches in cell lines and primary cells demonstrating pathway activation; 375 citations","pmids":["19641190"],"is_preprint":false},{"year":2009,"finding":"CRLF2 is a type I cytokine receptor subunit that can substitute for IL-3 signaling in a functional screen; a gain-of-function CRLF2 F232C mutation promotes constitutive dimerization and cytokine-independent growth; CRLF2 serves as the key scaffold for mutant JAK2 signaling in B-ALL, as all B-ALLs with mutant JAK2 overexpress CRLF2.","method":"Functional mRNA screen in IL-3-dependent cells, mutagenesis, Ba/F3 transformation assay, JAK2 phosphorylation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — functional screen plus mutagenesis plus signaling assays; multiple orthogonal methods; 270 citations","pmids":["20018760"],"is_preprint":false},{"year":2009,"finding":"The CRLF2 F232C gain-of-function mutation was identified in DS-ALL; mutant CRLF2 (F232C) and mutant JAK2 (R683) cooperate to confer cytokine-independent growth to BaF3 pro-B cells.","method":"Somatic mutation sequencing, BaF3 cytokine-independent growth assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional cooperation demonstrated in BaF3 assay; corroborated by independent groups","pmids":["19965641"],"is_preprint":false},{"year":2010,"finding":"TSLP-mediated signaling through the CRLF2/IL-7Rα heterodimer requires at least one cytoplasmic tyrosine residue; unlike IL-7 signaling which requires Y449 in IL-7Rα, tyrosine residues in both CRLF2 and IL-7Rα play redundant roles in TSLP-dependent cell proliferation — mutation of all cytoplasmic tyrosines in both chains abolishes proliferation.","method":"Site-directed mutagenesis, Ba/F3 cell proliferation assay","journal":"BMC immunology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with functional readout establishing mechanism of signal transduction through the receptor complex","pmids":["20144186"],"is_preprint":false},{"year":2012,"finding":"CRLF2-rearranged ALL shows increased basal levels of pJAK2, pSTAT5, and pS6; TSLP stimulation of these leukemias induces robust JAK/STAT and PI3K/mTOR pathway signaling; JAK inhibition abrogates phosphorylation of both JAK/STAT and PI3K/mTOR pathway members, demonstrating interconnection between these signaling networks.","method":"Phospho-flow cytometry of primary patient samples, TSLP stimulation assays, JAK inhibitor treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — analysis of primary patient samples with multiple signaling readouts and pharmacological perturbation; 189 citations","pmids":["22685175"],"is_preprint":false},{"year":2012,"finding":"CRLF2 signaling differs depending on mutational context: CRLF2 F232C signaling uniquely requires intracellular tyrosine Y368, while TSLP-induced or mutant JAK2-driven signaling does not; all three contexts strictly require the CRLF2 box1 domain and intracellular tryptophan W286; cells with CRLF2/mutant JAK2 show reduced phosphorylation of B-cell receptor-associated kinases (Lyn, Btk, Hck, Syk) compared to TSLP-stimulated cells, suggesting these kinases are negative regulators in the mutant JAK2 context.","method":"Domain mutagenesis analysis, global quantitative phosphotyrosine profiling, Ba/F3 signaling assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with global phosphoproteomics defining distinct signaling requirements for each mutational context","pmids":["22915648"],"is_preprint":false},{"year":2015,"finding":"TSLPR (CRLF2) is expressed on the surface of CRLF2-overexpressing B-ALL cells and can be targeted by chimeric antigen receptor T cells (TSLPR CAR T cells) with potent in vivo leukemia-eradicating activity; short TSLPR CARs (but not long CARs) mediate leukemia regression and long-term CAR T cell persistence in xenograft models.","method":"CAR T cell construction, in vitro cytotoxicity assay, in vivo xenograft models (4 models)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo xenograft models demonstrating CRLF2 surface expression is functionally targetable; 106 citations","pmids":["26041741"],"is_preprint":false},{"year":2015,"finding":"Human TSLP (but not mouse TSLP) activates JAK/STAT5 and PI3K/AKT/mTOR downstream pathways in CRLF2-overexpressing primary leukemia cells, demonstrating species-specific ligand-receptor signaling.","method":"Cytokine stimulation assays with phospho-signaling readouts, xenograft model comparison","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — functional signaling assay with multiple pathway readouts in primary leukemia cells","pmids":["26611474"],"is_preprint":false},{"year":2016,"finding":"The IKZF1-encoded protein Ikaros directly binds to the CRLF2 promoter and suppresses CRLF2 expression in leukemia cells through enrichment of H3K9me3 histone modifications; CK2 inhibitor increases Ikaros binding to the CRLF2 promoter and suppresses CRLF2 expression in an Ikaros-dependent manner.","method":"ChIP assay, CK2 inhibitor treatment, promoter binding analysis, histone modification assay","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP demonstrating protein-DNA interaction with functional consequence; multiple orthogonal approaches","pmids":["27391346"],"is_preprint":false},{"year":2019,"finding":"CRLF2 rearrangement-driven aberrant signal transduction mediates relative glucocorticoid resistance; targeted inhibition of MEK (trametinib) or Akt (MK2206), but not JAK inhibition (ruxolitinib), was sufficient to augment glucocorticoid sensitivity in CRLF2-rearranged ALL patient-derived xenografts.","method":"Patient-derived xenograft ex vivo drug sensitivity assays, targeted kinase inhibitor treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis in PDX models linking CRLF2-driven signaling to glucocorticoid resistance mechanism","pmids":["31318944"],"is_preprint":false},{"year":2021,"finding":"JAK-directed PROTACs that degrade JAK2 via cereblon (CRBN) potently kill CRLF2-rearranged ALL cell lines; solving the structure of ruxolitinib and baricitinib bound to the JAK2 tyrosine kinase domain enabled rational PROTAC design; dual JAK/GSPT1-degrading PROTACs were most potent, while a JAK2-specific PROTAC (SJ1008030) showed efficacy in vivo in kinase-driven xenografts resistant to type I JAK inhibitors.","method":"Crystal structure of JAK inhibitors bound to JAK2, PROTAC synthesis and optimization, cell line and xenograft efficacy testing","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — structure-guided drug design with functional validation in cell lines and multiple in vivo xenograft models","pmids":["34110416"],"is_preprint":false},{"year":2021,"finding":"HMGN1 overexpression in murine stem cells and Ba/F3 cells in combination with P2RY8-CRLF2 results in cytokine-independent transformation and upregulation of JAK/STAT cell signaling pathways associated with leukemic development; HMGN1 knockout in an inducible CRISPR/Cas9 xenograft model mitigated leukemic phenotypes and increased survival.","method":"CRISPR/Cas9 knockout xenograft model, Ba/F3 cytokine-independent transformation assay, in vivo leukemia burden assessment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — functional transformation assay plus in vivo KO model with multiple phenotypic readouts","pmids":["34857887"],"is_preprint":false},{"year":2022,"finding":"CRKL depletion enhances ruxolitinib sensitivity in RAS wild-type IgH-CRLF2-rearranged ALL cells; STAT5A, STAT5B, and STAT3 are largely dispensable for IgH-CRLF2-r ALL cell survival (genome-wide CRISPR screen); regulators of RAS signaling are critical for cell fitness and ruxolitinib sensitivity.","method":"Genome-wide CRISPR-Cas9 dropout screen, genetic depletion, in vitro and in vivo drug testing","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — unbiased genome-wide genetic screen with functional validation in vitro and in vivo","pmids":["34587248"],"is_preprint":false},{"year":2022,"finding":"CRLF2 overexpression in Dp16 (Down syndrome model) B-progenitor cells results in reduced B-cell differentiation, increased less-differentiated pre-pro-B cell proportions, and upregulated E2F signaling; CRLF2 overexpression alone did not cause leukemic transformation in recipient mice, indicating cooperating events are required.","method":"Dp16 mouse model, CRLF2 retroviral overexpression, immunophenotyping, gene expression profiling, colony assay","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — functional mouse model with gene expression profiling establishing a specific cellular phenotype","pmids":["35306048"],"is_preprint":false},{"year":2023,"finding":"HMGN1 expression increases the propensity for P2RY8::CRLF2 fusion generation; using a CRISPR/Cas9 system to induce DNA breaks at the PAR region, cells expressing HMGN1 preferentially repaired with P2RY8::CRLF2 formation compared to control cells; P2RY8::CRLF2 cells expressing HMGN1 exhibited increased proliferation, TSLPR expression, and JAK/STAT signaling.","method":"Inducible CRISPR/Cas9 modeling of PAR deletion, HMGN1 overexpression, proliferation assays, signaling pathway analysis","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic CRISPR model directly demonstrating HMGN1 influence on P2RY8::CRLF2 formation and downstream signaling","pmids":["37483494"],"is_preprint":false},{"year":2020,"finding":"TSLP stimulation of CRLF2-rearranged Ph-like ALL cells increases phosphorylation of JAK1, JAK2, STAT5, ERK1/2, as well as IGF1R and FGFR1; TSLP signaling is also associated with activation of the Rap1 signaling pathway in CRLF2-rearranged Ph-like ALL.","method":"Phosphotyrosine (P-Tyr) profiling with SILAC mass spectrometry in CRLF2r cell lines stimulated with TSLP","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 — quantitative phosphoproteomics with stable isotope labeling identifying downstream kinase substrates of TSLP/CRLF2 signaling","pmids":["32801162"],"is_preprint":false},{"year":2018,"finding":"CRLF2-driven signaling in B-ALL involves co-activation of JAK/STAT, PI3K, and CREB pathways; SRC/ABL inhibition more effectively disrupts this coordinated signaling network than single-agent JAK or PI3K inhibition, including in primary minimal residual disease cells.","method":"Single-cell mass cytometry (CyTOF) of 15 primary B-ALL patient samples, pharmacological inhibitor treatment","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — single-cell proteomics in primary patient samples defining coordinated signaling downstream of CRLF2","pmids":["29796158"],"is_preprint":false},{"year":2023,"finding":"BCL6 expression is upregulated upon JAK1/2 inhibition (ruxolitinib) in CRLF2-rearranged ALL cells; elevated BCL6 suppresses TP53 and downstream pro-apoptotic molecules (FAS, TNFRSF10B, BID, BAX, BAK, PUMA, NOXA), conferring resistance to therapy; BCL6 inhibition restores TP53 expression and augments apoptosis sensitivity.","method":"Gene expression analysis after ruxolitinib treatment, BCL6 inhibition (FX1), xenograft survival assay","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — mechanism of resistance identified by gene expression analysis with functional validation in vivo","pmids":["36005560"],"is_preprint":false},{"year":2022,"finding":"A novel scFv antibody fragment targeting the extracellular domain of CRLF2 (TSLPR) demonstrates receptor antagonistic effects on STAT5 signaling in CRLF2-overexpressing ALL cells, confirming that antibody binding to the CRLF2 ectodomain can block downstream JAK/STAT signaling.","method":"scFv development, CRLF2 knockdown cell line validation, STAT5 phosphorylation assay, patient-derived xenograft ex vivo association studies","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2-3 — receptor antagonism demonstrated by phospho-STAT5 inhibition with antibody targeting extracellular domain","pmids":["34481852"],"is_preprint":false}],"current_model":"CRLF2 encodes a type I cytokine receptor subunit that heterodimerizes with IL-7Rα to form the TSLP receptor complex; upon TSLP binding or through gain-of-function mutations (F232C causing constitutive dimerization) or genomic rearrangements (P2RY8-CRLF2, IGH-CRLF2) causing overexpression, CRLF2 activates JAK1/2-STAT5 and interconnected PI3K/mTOR signaling pathways via intracellular box1/box2 motifs and cytoplasmic tyrosine residues, with mutant JAK2 (R683) and HMGN1 overexpression cooperating to drive cytokine-independent proliferation and B-cell precursor leukemogenesis, while Ikaros (IKZF1) acts as a direct transcriptional repressor of CRLF2 expression through H3K9me3 promoter enrichment."},"narrative":{"teleology":[{"year":2001,"claim":"Identification of CRLF2 as a novel type I cytokine receptor with characteristic structural domains established its membership in the cytokine receptor family and its pseudoautosomal chromosomal location.","evidence":"cDNA library screening, Northern blot, and FISH mapping in human tissues","pmids":["11474172","11237741"],"confidence":"High","gaps":["Ligand identity unknown at this stage","No signaling pathway activation demonstrated","Physiological function undetermined"]},{"year":2002,"claim":"Demonstrating that CRLF2 heterodimerizes with IL-7Rα to form the functional TSLP receptor resolved the receptor composition question and linked CRLF2 to TSLP-mediated immune signaling.","evidence":"cDNA cloning, sequence analysis, and genomic structure characterization across species","pmids":["11891057"],"confidence":"High","gaps":["Signaling mechanism downstream of receptor engagement not yet defined","Role of individual intracellular residues unknown"]},{"year":2009,"claim":"Discovery of P2RY8-CRLF2 and IGH-CRLF2 rearrangements causing overexpression, the F232C gain-of-function mutation causing constitutive dimerization, and cooperation with mutant JAK2 for cytokine-independent transformation established CRLF2 as a central oncogenic scaffold in B-ALL.","evidence":"Genomic deletion analysis, Ba/F3 transformation assays, JAK-STAT signaling assays, and primary B-cell progenitor transduction across multiple independent groups","pmids":["19838194","19641190","20018760","19965641"],"confidence":"High","gaps":["Detailed intracellular signaling requirements not dissected","Whether CRLF2 overexpression alone is sufficient for transformation unclear","In vivo leukemogenesis models not yet established"]},{"year":2010,"claim":"Systematic mutagenesis established that TSLP signaling through the CRLF2/IL-7Rα complex requires at least one cytoplasmic tyrosine residue in either chain, distinguishing TSLP from IL-7 signaling which depends specifically on IL-7Rα Y449.","evidence":"Site-directed mutagenesis of all cytoplasmic tyrosines in both receptor chains with Ba/F3 proliferation readout","pmids":["20144186"],"confidence":"High","gaps":["Identity of specific signaling molecules recruited to CRLF2 tyrosines not established","Role of box1/box2 motifs not yet systematically tested"]},{"year":2012,"claim":"Domain dissection revealed that CRLF2 box1 and W286 are universally required for signaling, while Y368 is selectively required for F232C-driven but not TSLP- or mutant JAK2-driven signaling, establishing distinct intracellular wiring for different oncogenic contexts; concurrently, primary patient samples demonstrated interconnected JAK/STAT and PI3K/mTOR pathway activation downstream of CRLF2.","evidence":"Systematic domain mutagenesis with global quantitative phosphoproteomics in Ba/F3 cells; phospho-flow cytometry with JAK inhibitor treatment in primary CRLF2-rearranged ALL patient samples","pmids":["22915648","22685175"],"confidence":"High","gaps":["Structural basis for differential Y368 requirement unknown","Direct kinase-substrate relationships within the PI3K/mTOR branch not mapped"]},{"year":2016,"claim":"Identifying Ikaros as a direct transcriptional repressor of CRLF2 via H3K9me3 promoter enrichment provided a mechanism explaining how IKZF1 loss-of-function mutations lead to aberrant CRLF2 upregulation in leukemia.","evidence":"ChIP assay demonstrating direct Ikaros binding to CRLF2 promoter, CK2 inhibitor treatment modulating Ikaros–CRLF2 promoter interaction","pmids":["27391346"],"confidence":"High","gaps":["Whether other transcription factors co-regulate CRLF2 promoter not addressed","Chromatin-level mechanism beyond H3K9me3 not explored"]},{"year":2018,"claim":"Single-cell proteomics revealed that CRLF2-driven signaling in primary B-ALL involves coordinated co-activation of JAK/STAT, PI3K, and CREB pathways, and that SRC/ABL inhibition disrupts this network more effectively than JAK or PI3K inhibition alone.","evidence":"CyTOF mass cytometry of 15 primary B-ALL patient samples with pharmacological perturbation","pmids":["29796158"],"confidence":"Medium","gaps":["Direct physical link between CRLF2 and SRC family kinases not demonstrated","Whether CREB activation is direct or indirect unknown"]},{"year":2020,"claim":"Quantitative phosphoproteomics of TSLP-stimulated CRLF2-rearranged cells expanded the signaling landscape to include phosphorylation of IGF1R, FGFR1, and Rap1 pathway components, revealing broader receptor cross-talk than previously appreciated.","evidence":"SILAC-based phosphotyrosine profiling in CRLF2-rearranged cell lines stimulated with TSLP","pmids":["32801162"],"confidence":"High","gaps":["Whether IGF1R/FGFR1 phosphorylation is a direct consequence of CRLF2 signaling or a secondary effect not resolved","Functional significance of Rap1 pathway activation in leukemogenesis untested"]},{"year":2021,"claim":"HMGN1 overexpression was shown to cooperate with P2RY8-CRLF2 to drive cytokine-independent transformation and enhance JAK/STAT signaling, while also promoting P2RY8::CRLF2 fusion formation itself, establishing HMGN1 as both a predisposing and cooperating factor in CRLF2-driven leukemogenesis.","evidence":"Ba/F3 transformation assay, CRISPR/Cas9 knockout xenograft model, inducible PAR deletion model with HMGN1 expression","pmids":["34857887","37483494"],"confidence":"High","gaps":["Mechanism by which HMGN1 promotes preferential repair to form P2RY8::CRLF2 fusion not defined at the molecular level","Whether HMGN1-mediated chromatin changes directly alter CRLF2 locus accessibility unknown"]},{"year":2022,"claim":"A genome-wide CRISPR screen revealed that STAT5A/B and STAT3 are largely dispensable for CRLF2-rearranged ALL cell survival, while RAS pathway regulators including CRKL are critical for fitness and ruxolitinib sensitivity, reframing the signaling dependencies of CRLF2-driven leukemia.","evidence":"Genome-wide CRISPR-Cas9 dropout screen with genetic depletion and in vivo drug testing in IgH-CRLF2-rearranged ALL cells","pmids":["34587248"],"confidence":"High","gaps":["Why STAT5 is dispensable despite being prominently phosphorylated is mechanistically unexplained","Whether RAS dependency generalizes to P2RY8-CRLF2 contexts not tested"]},{"year":2022,"claim":"CRLF2 overexpression in a Down syndrome B-progenitor model impaired B-cell differentiation and upregulated E2F signaling but was insufficient for transformation, formally demonstrating the requirement for cooperating events.","evidence":"Dp16 mouse model with CRLF2 retroviral overexpression, immunophenotyping, and gene expression profiling","pmids":["35306048"],"confidence":"Medium","gaps":["Which cooperating mutations are minimally sufficient with CRLF2 overexpression for transformation not defined in this model","Relevance of E2F upregulation to leukemogenesis not functionally tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the CRLF2/IL-7Rα/TSLP ternary complex, why STAT5 is dispensable despite robust phosphorylation in CRLF2-rearranged ALL, the identity of direct kinase substrates linking CRLF2 to RAS and PI3K pathway activation, and the minimal cooperating genetic events required for CRLF2-driven leukemic transformation in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of the CRLF2-containing receptor complex","Mechanism of STAT5 dispensability in CRLF2-rearranged ALL unexplained","Minimal cooperating oncogenomic lesion set for CRLF2-driven transformation undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,7,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,10,22]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,7,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,4,5,6,15]}],"complexes":["TSLP receptor (CRLF2/IL-7Rα heterodimer)"],"partners":["IL7R","JAK2","JAK1","STAT5A","STAT5B","IKZF1","HMGN1","CRKL"],"other_free_text":[]},"mechanistic_narrative":"CRLF2 encodes a type I cytokine receptor subunit that heterodimerizes with IL-7Rα to form the functional receptor for thymic stromal lymphopoietin (TSLP), transducing signals through JAK1/2–STAT5 and PI3K/mTOR pathways via intracellular box1 domain and cytoplasmic tyrosine residues [PMID:11891057, PMID:20144186, PMID:22915648]. Genomic rearrangements (P2RY8-CRLF2, IGH-CRLF2) causing CRLF2 overexpression, or the gain-of-function F232C mutation promoting constitutive dimerization, cooperate with JAK2 pseudokinase domain mutations to drive cytokine-independent proliferation and B-cell precursor acute lymphoblastic leukemia, with TSLP stimulation additionally activating ERK1/2, Rap1, and CREB signaling networks [PMID:19838194, PMID:20018760, PMID:22685175, PMID:32801162]. CRLF2 overexpression in B-progenitor cells impairs B-cell differentiation and upregulates E2F signaling but is insufficient for leukemic transformation without cooperating genetic events such as mutant JAK2 or HMGN1 overexpression [PMID:35306048, PMID:34857887]. Ikaros (IKZF1) directly represses CRLF2 transcription through H3K9me3 enrichment at the CRLF2 promoter, and loss of this repression contributes to aberrant CRLF2 expression in leukemia [PMID:27391346]."},"prefetch_data":{"uniprot":{"accession":"Q9HC73","full_name":"Cytokine receptor-like factor 2","aliases":["Cytokine receptor-like 2","IL-XR","Thymic stromal lymphopoietin protein receptor","TSLP receptor"],"length_aa":371,"mass_kda":42.0,"function":"Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2 (By similarity). Implicated in the development of the hematopoietic system","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9HC73/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CRLF2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":74,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CRLF2","total_profiled":1310},"omim":[{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"607003","title":"THYMIC STROMAL LYMPHOPOIETIN; TSLP","url":"https://www.omim.org/entry/607003"},{"mim_id":"400023","title":"CYTOKINE RECEPTOR-LIKE FACTOR 2, Y-LINKED; CRLF2Y","url":"https://www.omim.org/entry/400023"},{"mim_id":"300525","title":"PYRIMIDINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 8; P2RY8","url":"https://www.omim.org/entry/300525"},{"mim_id":"300357","title":"CYTOKINE RECEPTOR-LIKE FACTOR 2; CRLF2","url":"https://www.omim.org/entry/300357"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":1.7},{"tissue":"gallbladder","ntpm":1.2},{"tissue":"lymphoid tissue","ntpm":1.4}],"url":"https://www.proteinatlas.org/search/CRLF2"},"hgnc":{"alias_symbol":["CRL2","TSLPR"],"prev_symbol":[]},"alphafold":{"accession":"Q9HC73","domains":[{"cath_id":"2.60.40.10","chopping":"29-116","consensus_level":"high","plddt":94.2113,"start":29,"end":116},{"cath_id":"2.60.40.10","chopping":"120-214","consensus_level":"high","plddt":95.902,"start":120,"end":214}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HC73","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HC73-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HC73-F1-predicted_aligned_error_v6.png","plddt_mean":77.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CRLF2","jax_strain_url":"https://www.jax.org/strain/search?query=CRLF2"},"sequence":{"accession":"Q9HC73","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HC73.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HC73/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HC73"}},"corpus_meta":[{"pmid":"19838194","id":"PMC_19838194","title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19838194","citation_count":458,"is_preprint":false},{"pmid":"20139093","id":"PMC_20139093","title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20139093","citation_count":441,"is_preprint":false},{"pmid":"19641190","id":"PMC_19641190","title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19641190","citation_count":375,"is_preprint":false},{"pmid":"20018760","id":"PMC_20018760","title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20018760","citation_count":270,"is_preprint":false},{"pmid":"19965641","id":"PMC_19965641","title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19965641","citation_count":265,"is_preprint":false},{"pmid":"22368272","id":"PMC_22368272","title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22368272","citation_count":195,"is_preprint":false},{"pmid":"22685175","id":"PMC_22685175","title":"Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22685175","citation_count":189,"is_preprint":false},{"pmid":"29775578","id":"PMC_29775578","title":"C-Terminal End-Directed Protein Elimination by CRL2 Ubiquitin Ligases.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29775578","citation_count":150,"is_preprint":false},{"pmid":"21106984","id":"PMC_21106984","title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21106984","citation_count":112,"is_preprint":false},{"pmid":"26041741","id":"PMC_26041741","title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26041741","citation_count":106,"is_preprint":false},{"pmid":"22851563","id":"PMC_22851563","title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.","date":"2012","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22851563","citation_count":106,"is_preprint":false},{"pmid":"28235849","id":"PMC_28235849","title":"CRL2Lrr1 promotes unloading of the vertebrate replisome from chromatin during replication termination.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28235849","citation_count":96,"is_preprint":false},{"pmid":"22441210","id":"PMC_22441210","title":"Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22441210","citation_count":86,"is_preprint":false},{"pmid":"30526872","id":"PMC_30526872","title":"Recognition of the Diglycine C-End Degron by CRL2KLHDC2 Ubiquitin Ligase.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30526872","citation_count":84,"is_preprint":false},{"pmid":"22168549","id":"PMC_22168549","title":"Function and mechanisms of TSLP/TSLPR complex in asthma and COPD.","date":"2011","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22168549","citation_count":72,"is_preprint":false},{"pmid":"21352203","id":"PMC_21352203","title":"A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells.","date":"2011","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21352203","citation_count":67,"is_preprint":false},{"pmid":"26138980","id":"PMC_26138980","title":"SELENOPROTEINS. CRL2 aids elimination of truncated selenoproteins produced by failed UGA/Sec decoding.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26138980","citation_count":62,"is_preprint":false},{"pmid":"34110416","id":"PMC_34110416","title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34110416","citation_count":60,"is_preprint":false},{"pmid":"22838633","id":"PMC_22838633","title":"IL-3 and TNFα increase Thymic Stromal Lymphopoietin Receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation.","date":"2012","source":"Clinical and molecular allergy : CMA","url":"https://pubmed.ncbi.nlm.nih.gov/22838633","citation_count":56,"is_preprint":false},{"pmid":"11474172","id":"PMC_11474172","title":"Molecular cloning of a human novel type I cytokine receptor related to delta1/TSLPR.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11474172","citation_count":54,"is_preprint":false},{"pmid":"23091296","id":"PMC_23091296","title":"Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23091296","citation_count":54,"is_preprint":false},{"pmid":"21074724","id":"PMC_21074724","title":"CRL2(LRR-1) targets a CDK inhibitor for cell cycle control in C. elegans and actin-based motility regulation in human cells.","date":"2010","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/21074724","citation_count":52,"is_preprint":false},{"pmid":"20807819","id":"PMC_20807819","title":"CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20807819","citation_count":52,"is_preprint":false},{"pmid":"28033648","id":"PMC_28033648","title":"Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.","date":"2017","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28033648","citation_count":51,"is_preprint":false},{"pmid":"28340183","id":"PMC_28340183","title":"CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.","date":"2017","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28340183","citation_count":47,"is_preprint":false},{"pmid":"27899802","id":"PMC_27899802","title":"Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27899802","citation_count":46,"is_preprint":false},{"pmid":"29487712","id":"PMC_29487712","title":"Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29487712","citation_count":44,"is_preprint":false},{"pmid":"26754556","id":"PMC_26754556","title":"CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.","date":"2015","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26754556","citation_count":43,"is_preprint":false},{"pmid":"22915648","id":"PMC_22915648","title":"Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22915648","citation_count":40,"is_preprint":false},{"pmid":"27391346","id":"PMC_27391346","title":"High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27391346","citation_count":36,"is_preprint":false},{"pmid":"34214466","id":"PMC_34214466","title":"Molecular basis for recognition of Gly/N-degrons by CRL2ZYG11B and CRL2ZER1.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34214466","citation_count":35,"is_preprint":false},{"pmid":"28331226","id":"PMC_28331226","title":"The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28331226","citation_count":35,"is_preprint":false},{"pmid":"23555289","id":"PMC_23555289","title":"CRL2(LRR-1) E3-ligase regulates proliferation and progression through meiosis in the Caenorhabditis elegans germline.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23555289","citation_count":35,"is_preprint":false},{"pmid":"22816614","id":"PMC_22816614","title":"Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.","date":"2012","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/22816614","citation_count":35,"is_preprint":false},{"pmid":"32160551","id":"PMC_32160551","title":"NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32160551","citation_count":34,"is_preprint":false},{"pmid":"22150304","id":"PMC_22150304","title":"Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.","date":"2011","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22150304","citation_count":33,"is_preprint":false},{"pmid":"33398170","id":"PMC_33398170","title":"Molecular basis for ubiquitin ligase CRL2FEM1C-mediated recognition of C-degron.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33398170","citation_count":32,"is_preprint":false},{"pmid":"34743205","id":"PMC_34743205","title":"CRL2-KLHDC3 E3 ubiquitin ligase complex suppresses ferroptosis through promoting p14ARF degradation.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34743205","citation_count":32,"is_preprint":false},{"pmid":"28341671","id":"PMC_28341671","title":"Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+ CD1c+ Monocytes.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28341671","citation_count":29,"is_preprint":false},{"pmid":"24935070","id":"PMC_24935070","title":"An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression.","date":"2014","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24935070","citation_count":27,"is_preprint":false},{"pmid":"27107416","id":"PMC_27107416","title":"Atlas on substrate recognition subunits of CRL2 E3 ligases.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27107416","citation_count":26,"is_preprint":false},{"pmid":"11237741","id":"PMC_11237741","title":"Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11237741","citation_count":26,"is_preprint":false},{"pmid":"33895784","id":"PMC_33895784","title":"Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/33895784","citation_count":26,"is_preprint":false},{"pmid":"36496439","id":"PMC_36496439","title":"CRL2ZER1/ZYG11B recognizes small N-terminal residues for degradation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36496439","citation_count":25,"is_preprint":false},{"pmid":"33504946","id":"PMC_33504946","title":"Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2Prame complex.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/33504946","citation_count":25,"is_preprint":false},{"pmid":"26611474","id":"PMC_26611474","title":"A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26611474","citation_count":25,"is_preprint":false},{"pmid":"31318944","id":"PMC_31318944","title":"CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31318944","citation_count":24,"is_preprint":false},{"pmid":"28866095","id":"PMC_28866095","title":"Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28866095","citation_count":22,"is_preprint":false},{"pmid":"31350466","id":"PMC_31350466","title":"Short ragweed pollen promotes M2 macrophage polarization via TSLP/TSLPR/OX40L signaling in allergic inflammation.","date":"2019","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31350466","citation_count":20,"is_preprint":false},{"pmid":"30487598","id":"PMC_30487598","title":"Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30487598","citation_count":20,"is_preprint":false},{"pmid":"33444648","id":"PMC_33444648","title":"UBXN7 cofactor of CRL3KEAP1 and CRL2VHL ubiquitin ligase complexes mediates reciprocal regulation of NRF2 and HIF-1α proteins.","date":"2021","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33444648","citation_count":19,"is_preprint":false},{"pmid":"25591759","id":"PMC_25591759","title":"Inflammatory cytokine TSLP stimulates platelet secretion and potentiates platelet aggregation via a TSLPR-dependent PI3K/Akt signaling pathway.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25591759","citation_count":19,"is_preprint":false},{"pmid":"34857887","id":"PMC_34857887","title":"HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34857887","citation_count":19,"is_preprint":false},{"pmid":"38670995","id":"PMC_38670995","title":"Mechanism of Ψ-Pro/C-degron recognition by the CRL2FEM1B ubiquitin ligase.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38670995","citation_count":18,"is_preprint":false},{"pmid":"26874828","id":"PMC_26874828","title":"A potential link between TSLP/TSLPR/STAT5 and TLR2/MyD88/NFκB-p65 in human corneal epithelial cells for Aspergillus fumigatus tolerance.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26874828","citation_count":18,"is_preprint":false},{"pmid":"37676773","id":"PMC_37676773","title":"Mechanism and evolutionary origins of alanine-tail C-degron recognition by E3 ligases Pirh2 and CRL2-KLHDC10.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37676773","citation_count":17,"is_preprint":false},{"pmid":"38170390","id":"PMC_38170390","title":"CRL2APPBP2-mediated TSPYL2 degradation counteracts human mesenchymal stem cell senescence.","date":"2023","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38170390","citation_count":17,"is_preprint":false},{"pmid":"34587248","id":"PMC_34587248","title":"Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34587248","citation_count":17,"is_preprint":false},{"pmid":"25544178","id":"PMC_25544178","title":"Disruption of the TSLP-TSLPR-LAP signaling between epithelial and dendritic cells through hyperlipidemia contributes to regulatory T-Cell defects in atherosclerotic mice.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25544178","citation_count":17,"is_preprint":false},{"pmid":"37844242","id":"PMC_37844242","title":"Molecular basis for C-degron recognition by CRL2APPBP2 ubiquitin ligase.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37844242","citation_count":14,"is_preprint":false},{"pmid":"25117469","id":"PMC_25117469","title":"TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.","date":"2014","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25117469","citation_count":14,"is_preprint":false},{"pmid":"34159401","id":"PMC_34159401","title":"Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.","date":"2021","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/34159401","citation_count":14,"is_preprint":false},{"pmid":"34459035","id":"PMC_34459035","title":"Quantitative analyses for effects of neddylation on CRL2VHL substrate ubiquitination and degradation.","date":"2021","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/34459035","citation_count":12,"is_preprint":false},{"pmid":"35468939","id":"PMC_35468939","title":"CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35468939","citation_count":12,"is_preprint":false},{"pmid":"36029577","id":"PMC_36029577","title":"Nonylphenol exacerbates ovalbumin-induced allergic rhinitis via the TSLP-TSLPR/IL-7R pathway and JAK1/2-STAT3 signaling in a mouse model.","date":"2022","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/36029577","citation_count":11,"is_preprint":false},{"pmid":"20144186","id":"PMC_20144186","title":"Site-directed mutagenesis reveals a unique requirement for tyrosine residues in IL-7Ralpha and TSLPR cytoplasmic domains in TSLP-dependent cell proliferation.","date":"2010","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20144186","citation_count":11,"is_preprint":false},{"pmid":"36814093","id":"PMC_36814093","title":"Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.","date":"2023","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/36814093","citation_count":11,"is_preprint":false},{"pmid":"29796158","id":"PMC_29796158","title":"SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29796158","citation_count":11,"is_preprint":false},{"pmid":"25044358","id":"PMC_25044358","title":"Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.","date":"2014","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25044358","citation_count":11,"is_preprint":false},{"pmid":"36005560","id":"PMC_36005560","title":"BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/36005560","citation_count":10,"is_preprint":false},{"pmid":"29257253","id":"PMC_29257253","title":"TSLP/TSLPR promote angiogenesis following ischemic stroke via activation of the PI3K/AKT pathway.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29257253","citation_count":10,"is_preprint":false},{"pmid":"29222519","id":"PMC_29222519","title":"Virtual screening for inhibitors of the human TSLP:TSLPR interaction.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29222519","citation_count":10,"is_preprint":false},{"pmid":"32309281","id":"PMC_32309281","title":"Combinatorial IL-17RB, ST2, and TSLPR Signaling in Dendritic Cells of Patients With Allergic Rhinitis.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32309281","citation_count":10,"is_preprint":false},{"pmid":"28233860","id":"PMC_28233860","title":"Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28233860","citation_count":10,"is_preprint":false},{"pmid":"29140408","id":"PMC_29140408","title":"Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation.","date":"2017","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29140408","citation_count":9,"is_preprint":false},{"pmid":"37634013","id":"PMC_37634013","title":"Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37634013","citation_count":8,"is_preprint":false},{"pmid":"37483494","id":"PMC_37483494","title":"Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37483494","citation_count":8,"is_preprint":false},{"pmid":"35537330","id":"PMC_35537330","title":"High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.","date":"2022","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/35537330","citation_count":8,"is_preprint":false},{"pmid":"40082426","id":"PMC_40082426","title":"Identification of a non-inhibitory aptameric ligand to CRL2ZYG11B E3 ligase for targeted protein degradation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40082426","citation_count":8,"is_preprint":false},{"pmid":"30859636","id":"PMC_30859636","title":"GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.","date":"2019","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30859636","citation_count":8,"is_preprint":false},{"pmid":"35253299","id":"PMC_35253299","title":"CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35253299","citation_count":7,"is_preprint":false},{"pmid":"37364323","id":"PMC_37364323","title":"TSLP/TSLPR promotes renal fibrosis by activating STAT3 in renal fibroblasts.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37364323","citation_count":7,"is_preprint":false},{"pmid":"11891057","id":"PMC_11891057","title":"Cloning of rat thymic stromal lymphopoietin receptor (TSLPR) and characterization of genomic structure of murine Tslpr gene.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11891057","citation_count":7,"is_preprint":false},{"pmid":"23976822","id":"PMC_23976822","title":"Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL.","date":"2013","source":"Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems","url":"https://pubmed.ncbi.nlm.nih.gov/23976822","citation_count":7,"is_preprint":false},{"pmid":"35306048","id":"PMC_35306048","title":"CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.","date":"2022","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35306048","citation_count":6,"is_preprint":false},{"pmid":"29879498","id":"PMC_29879498","title":"Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29879498","citation_count":6,"is_preprint":false},{"pmid":"20663412","id":"PMC_20663412","title":"Identifying the polymorphisms in the thymic stromal lymphopoietin receptor (TSLPR) and their association with asthma.","date":"2010","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/20663412","citation_count":6,"is_preprint":false},{"pmid":"38370004","id":"PMC_38370004","title":"Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.","date":"2024","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/38370004","citation_count":6,"is_preprint":false},{"pmid":"33890726","id":"PMC_33890726","title":"CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.","date":"2021","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/33890726","citation_count":6,"is_preprint":false},{"pmid":"36613920","id":"PMC_36613920","title":"TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36613920","citation_count":5,"is_preprint":false},{"pmid":"39681640","id":"PMC_39681640","title":"Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39681640","citation_count":5,"is_preprint":false},{"pmid":"30578688","id":"PMC_30578688","title":"CRLF2 expression associates with ICN1 stabilization in T-cell acute lymphoblastic leukemia.","date":"2019","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30578688","citation_count":4,"is_preprint":false},{"pmid":"33491417","id":"PMC_33491417","title":"Characterization of CRLF2 Expression in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.","date":"2021","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/33491417","citation_count":4,"is_preprint":false},{"pmid":"32801162","id":"PMC_32801162","title":"Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32801162","citation_count":4,"is_preprint":false},{"pmid":"35159975","id":"PMC_35159975","title":"Metal Allergy Mediates the Development of Oral Lichen Planus via TSLP-TSLPR Signaling.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35159975","citation_count":4,"is_preprint":false},{"pmid":"38069558","id":"PMC_38069558","title":"An intrinsic network of polar interactions is responsible for binding of UL49.5 C-degron by the CRL2KLHDC3 ubiquitin ligase.","date":"2023","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/38069558","citation_count":4,"is_preprint":false},{"pmid":"34481852","id":"PMC_34481852","title":"A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.","date":"2021","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34481852","citation_count":4,"is_preprint":false},{"pmid":"38698266","id":"PMC_38698266","title":"CRL2KLHDC3 and CRL1Fbxw7 cooperatively mediate c-Myc degradation.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38698266","citation_count":4,"is_preprint":false},{"pmid":"39461880","id":"PMC_39461880","title":"CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39461880","citation_count":3,"is_preprint":false},{"pmid":"39071567","id":"PMC_39071567","title":"Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39071567","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53872,"output_tokens":5622,"usd":0.122973},"stage2":{"model":"claude-opus-4-6","input_tokens":9186,"output_tokens":3248,"usd":0.190695},"total_usd":0.313668,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"CRLF2 (cytokine receptor-like factor 2) was cloned as a novel type I cytokine receptor with an extracellular domain containing two fibronectin type III-like domains, four conserved cysteine residues, a WSXWS box-like motif, and an intracellular domain with box 1 and box 2-like motifs, mapping to the pseudoautosomal region Xp22.3/Yp11.3.\",\n      \"method\": \"cDNA library screening, Northern blot, FISH mapping\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper with multiple orthogonal methods establishing domain architecture and chromosomal location\",\n      \"pmids\": [\"11474172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CRLF2 (CRL2) is preferentially expressed on dendritic cells and activated monocytes, with expression upregulated by LPS stimulation; the intracellular domain contains a membrane-proximal box 1 motif and a conserved tyrosine residue as a potential binding site for signal transducing molecules.\",\n      \"method\": \"RT-PCR, Northern blot, immunoprecipitation of FLAG-tagged CRL2 in Ba/F3 transfectants\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — protein expression confirmed by immunoprecipitation, cell-type preference established by RT-PCR\",\n      \"pmids\": [\"11237741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TSLPR (CRLF2) forms a heterodimeric complex with the IL-7 receptor alpha chain to constitute the functional receptor for TSLP; the WSXWX motif in the extracellular domain is conserved across rat, mouse, and human TSLPR.\",\n      \"method\": \"cDNA cloning, sequence analysis, genomic structure characterization, zooblot analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor complex composition established by cloning and functional characterization; replicated across species\",\n      \"pmids\": [\"11891057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Interstitial deletion of the pseudoautosomal region 1 creates a P2RY8-CRLF2 fusion that juxtaposes the P2RY8 promoter with the CRLF2 coding region, causing CRLF2 overexpression; co-expression of P2RY8-CRLF2 with mutant mouse Jak2 results in constitutive JAK-STAT activation and cytokine-independent growth of Ba/F3 cells overexpressing IL-7Rα.\",\n      \"method\": \"Genomic deletion analysis, Ba/F3 cell transformation assay, JAK-STAT signaling assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional transformation assay with signaling readout; founding mechanistic paper with 458 citations\",\n      \"pmids\": [\"19838194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CRLF2 overexpression driven by IGH translocation or P2RY8-CRLF2 deletion activates the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining proliferation; CRLF2 deregulation cooperates with JAK2 pseudokinase domain mutations for oncogenic transformation.\",\n      \"method\": \"Flow cytometry-based proliferation assay, JAK-STAT pathway analysis, primary B-cell progenitor transduction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches in cell lines and primary cells demonstrating pathway activation; 375 citations\",\n      \"pmids\": [\"19641190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CRLF2 is a type I cytokine receptor subunit that can substitute for IL-3 signaling in a functional screen; a gain-of-function CRLF2 F232C mutation promotes constitutive dimerization and cytokine-independent growth; CRLF2 serves as the key scaffold for mutant JAK2 signaling in B-ALL, as all B-ALLs with mutant JAK2 overexpress CRLF2.\",\n      \"method\": \"Functional mRNA screen in IL-3-dependent cells, mutagenesis, Ba/F3 transformation assay, JAK2 phosphorylation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional screen plus mutagenesis plus signaling assays; multiple orthogonal methods; 270 citations\",\n      \"pmids\": [\"20018760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The CRLF2 F232C gain-of-function mutation was identified in DS-ALL; mutant CRLF2 (F232C) and mutant JAK2 (R683) cooperate to confer cytokine-independent growth to BaF3 pro-B cells.\",\n      \"method\": \"Somatic mutation sequencing, BaF3 cytokine-independent growth assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional cooperation demonstrated in BaF3 assay; corroborated by independent groups\",\n      \"pmids\": [\"19965641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TSLP-mediated signaling through the CRLF2/IL-7Rα heterodimer requires at least one cytoplasmic tyrosine residue; unlike IL-7 signaling which requires Y449 in IL-7Rα, tyrosine residues in both CRLF2 and IL-7Rα play redundant roles in TSLP-dependent cell proliferation — mutation of all cytoplasmic tyrosines in both chains abolishes proliferation.\",\n      \"method\": \"Site-directed mutagenesis, Ba/F3 cell proliferation assay\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional readout establishing mechanism of signal transduction through the receptor complex\",\n      \"pmids\": [\"20144186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CRLF2-rearranged ALL shows increased basal levels of pJAK2, pSTAT5, and pS6; TSLP stimulation of these leukemias induces robust JAK/STAT and PI3K/mTOR pathway signaling; JAK inhibition abrogates phosphorylation of both JAK/STAT and PI3K/mTOR pathway members, demonstrating interconnection between these signaling networks.\",\n      \"method\": \"Phospho-flow cytometry of primary patient samples, TSLP stimulation assays, JAK inhibitor treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — analysis of primary patient samples with multiple signaling readouts and pharmacological perturbation; 189 citations\",\n      \"pmids\": [\"22685175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CRLF2 signaling differs depending on mutational context: CRLF2 F232C signaling uniquely requires intracellular tyrosine Y368, while TSLP-induced or mutant JAK2-driven signaling does not; all three contexts strictly require the CRLF2 box1 domain and intracellular tryptophan W286; cells with CRLF2/mutant JAK2 show reduced phosphorylation of B-cell receptor-associated kinases (Lyn, Btk, Hck, Syk) compared to TSLP-stimulated cells, suggesting these kinases are negative regulators in the mutant JAK2 context.\",\n      \"method\": \"Domain mutagenesis analysis, global quantitative phosphotyrosine profiling, Ba/F3 signaling assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with global phosphoproteomics defining distinct signaling requirements for each mutational context\",\n      \"pmids\": [\"22915648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TSLPR (CRLF2) is expressed on the surface of CRLF2-overexpressing B-ALL cells and can be targeted by chimeric antigen receptor T cells (TSLPR CAR T cells) with potent in vivo leukemia-eradicating activity; short TSLPR CARs (but not long CARs) mediate leukemia regression and long-term CAR T cell persistence in xenograft models.\",\n      \"method\": \"CAR T cell construction, in vitro cytotoxicity assay, in vivo xenograft models (4 models)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo xenograft models demonstrating CRLF2 surface expression is functionally targetable; 106 citations\",\n      \"pmids\": [\"26041741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Human TSLP (but not mouse TSLP) activates JAK/STAT5 and PI3K/AKT/mTOR downstream pathways in CRLF2-overexpressing primary leukemia cells, demonstrating species-specific ligand-receptor signaling.\",\n      \"method\": \"Cytokine stimulation assays with phospho-signaling readouts, xenograft model comparison\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional signaling assay with multiple pathway readouts in primary leukemia cells\",\n      \"pmids\": [\"26611474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The IKZF1-encoded protein Ikaros directly binds to the CRLF2 promoter and suppresses CRLF2 expression in leukemia cells through enrichment of H3K9me3 histone modifications; CK2 inhibitor increases Ikaros binding to the CRLF2 promoter and suppresses CRLF2 expression in an Ikaros-dependent manner.\",\n      \"method\": \"ChIP assay, CK2 inhibitor treatment, promoter binding analysis, histone modification assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP demonstrating protein-DNA interaction with functional consequence; multiple orthogonal approaches\",\n      \"pmids\": [\"27391346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRLF2 rearrangement-driven aberrant signal transduction mediates relative glucocorticoid resistance; targeted inhibition of MEK (trametinib) or Akt (MK2206), but not JAK inhibition (ruxolitinib), was sufficient to augment glucocorticoid sensitivity in CRLF2-rearranged ALL patient-derived xenografts.\",\n      \"method\": \"Patient-derived xenograft ex vivo drug sensitivity assays, targeted kinase inhibitor treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis in PDX models linking CRLF2-driven signaling to glucocorticoid resistance mechanism\",\n      \"pmids\": [\"31318944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"JAK-directed PROTACs that degrade JAK2 via cereblon (CRBN) potently kill CRLF2-rearranged ALL cell lines; solving the structure of ruxolitinib and baricitinib bound to the JAK2 tyrosine kinase domain enabled rational PROTAC design; dual JAK/GSPT1-degrading PROTACs were most potent, while a JAK2-specific PROTAC (SJ1008030) showed efficacy in vivo in kinase-driven xenografts resistant to type I JAK inhibitors.\",\n      \"method\": \"Crystal structure of JAK inhibitors bound to JAK2, PROTAC synthesis and optimization, cell line and xenograft efficacy testing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided drug design with functional validation in cell lines and multiple in vivo xenograft models\",\n      \"pmids\": [\"34110416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HMGN1 overexpression in murine stem cells and Ba/F3 cells in combination with P2RY8-CRLF2 results in cytokine-independent transformation and upregulation of JAK/STAT cell signaling pathways associated with leukemic development; HMGN1 knockout in an inducible CRISPR/Cas9 xenograft model mitigated leukemic phenotypes and increased survival.\",\n      \"method\": \"CRISPR/Cas9 knockout xenograft model, Ba/F3 cytokine-independent transformation assay, in vivo leukemia burden assessment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional transformation assay plus in vivo KO model with multiple phenotypic readouts\",\n      \"pmids\": [\"34857887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRKL depletion enhances ruxolitinib sensitivity in RAS wild-type IgH-CRLF2-rearranged ALL cells; STAT5A, STAT5B, and STAT3 are largely dispensable for IgH-CRLF2-r ALL cell survival (genome-wide CRISPR screen); regulators of RAS signaling are critical for cell fitness and ruxolitinib sensitivity.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 dropout screen, genetic depletion, in vitro and in vivo drug testing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased genome-wide genetic screen with functional validation in vitro and in vivo\",\n      \"pmids\": [\"34587248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRLF2 overexpression in Dp16 (Down syndrome model) B-progenitor cells results in reduced B-cell differentiation, increased less-differentiated pre-pro-B cell proportions, and upregulated E2F signaling; CRLF2 overexpression alone did not cause leukemic transformation in recipient mice, indicating cooperating events are required.\",\n      \"method\": \"Dp16 mouse model, CRLF2 retroviral overexpression, immunophenotyping, gene expression profiling, colony assay\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mouse model with gene expression profiling establishing a specific cellular phenotype\",\n      \"pmids\": [\"35306048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMGN1 expression increases the propensity for P2RY8::CRLF2 fusion generation; using a CRISPR/Cas9 system to induce DNA breaks at the PAR region, cells expressing HMGN1 preferentially repaired with P2RY8::CRLF2 formation compared to control cells; P2RY8::CRLF2 cells expressing HMGN1 exhibited increased proliferation, TSLPR expression, and JAK/STAT signaling.\",\n      \"method\": \"Inducible CRISPR/Cas9 modeling of PAR deletion, HMGN1 overexpression, proliferation assays, signaling pathway analysis\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic CRISPR model directly demonstrating HMGN1 influence on P2RY8::CRLF2 formation and downstream signaling\",\n      \"pmids\": [\"37483494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TSLP stimulation of CRLF2-rearranged Ph-like ALL cells increases phosphorylation of JAK1, JAK2, STAT5, ERK1/2, as well as IGF1R and FGFR1; TSLP signaling is also associated with activation of the Rap1 signaling pathway in CRLF2-rearranged Ph-like ALL.\",\n      \"method\": \"Phosphotyrosine (P-Tyr) profiling with SILAC mass spectrometry in CRLF2r cell lines stimulated with TSLP\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative phosphoproteomics with stable isotope labeling identifying downstream kinase substrates of TSLP/CRLF2 signaling\",\n      \"pmids\": [\"32801162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRLF2-driven signaling in B-ALL involves co-activation of JAK/STAT, PI3K, and CREB pathways; SRC/ABL inhibition more effectively disrupts this coordinated signaling network than single-agent JAK or PI3K inhibition, including in primary minimal residual disease cells.\",\n      \"method\": \"Single-cell mass cytometry (CyTOF) of 15 primary B-ALL patient samples, pharmacological inhibitor treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single-cell proteomics in primary patient samples defining coordinated signaling downstream of CRLF2\",\n      \"pmids\": [\"29796158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCL6 expression is upregulated upon JAK1/2 inhibition (ruxolitinib) in CRLF2-rearranged ALL cells; elevated BCL6 suppresses TP53 and downstream pro-apoptotic molecules (FAS, TNFRSF10B, BID, BAX, BAK, PUMA, NOXA), conferring resistance to therapy; BCL6 inhibition restores TP53 expression and augments apoptosis sensitivity.\",\n      \"method\": \"Gene expression analysis after ruxolitinib treatment, BCL6 inhibition (FX1), xenograft survival assay\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanism of resistance identified by gene expression analysis with functional validation in vivo\",\n      \"pmids\": [\"36005560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A novel scFv antibody fragment targeting the extracellular domain of CRLF2 (TSLPR) demonstrates receptor antagonistic effects on STAT5 signaling in CRLF2-overexpressing ALL cells, confirming that antibody binding to the CRLF2 ectodomain can block downstream JAK/STAT signaling.\",\n      \"method\": \"scFv development, CRLF2 knockdown cell line validation, STAT5 phosphorylation assay, patient-derived xenograft ex vivo association studies\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — receptor antagonism demonstrated by phospho-STAT5 inhibition with antibody targeting extracellular domain\",\n      \"pmids\": [\"34481852\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CRLF2 encodes a type I cytokine receptor subunit that heterodimerizes with IL-7Rα to form the TSLP receptor complex; upon TSLP binding or through gain-of-function mutations (F232C causing constitutive dimerization) or genomic rearrangements (P2RY8-CRLF2, IGH-CRLF2) causing overexpression, CRLF2 activates JAK1/2-STAT5 and interconnected PI3K/mTOR signaling pathways via intracellular box1/box2 motifs and cytoplasmic tyrosine residues, with mutant JAK2 (R683) and HMGN1 overexpression cooperating to drive cytokine-independent proliferation and B-cell precursor leukemogenesis, while Ikaros (IKZF1) acts as a direct transcriptional repressor of CRLF2 expression through H3K9me3 promoter enrichment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CRLF2 encodes a type I cytokine receptor subunit that heterodimerizes with IL-7Rα to form the functional receptor for thymic stromal lymphopoietin (TSLP), transducing signals through JAK1/2–STAT5 and PI3K/mTOR pathways via intracellular box1 domain and cytoplasmic tyrosine residues [PMID:11891057, PMID:20144186, PMID:22915648]. Genomic rearrangements (P2RY8-CRLF2, IGH-CRLF2) causing CRLF2 overexpression, or the gain-of-function F232C mutation promoting constitutive dimerization, cooperate with JAK2 pseudokinase domain mutations to drive cytokine-independent proliferation and B-cell precursor acute lymphoblastic leukemia, with TSLP stimulation additionally activating ERK1/2, Rap1, and CREB signaling networks [PMID:19838194, PMID:20018760, PMID:22685175, PMID:32801162]. CRLF2 overexpression in B-progenitor cells impairs B-cell differentiation and upregulates E2F signaling but is insufficient for leukemic transformation without cooperating genetic events such as mutant JAK2 or HMGN1 overexpression [PMID:35306048, PMID:34857887]. Ikaros (IKZF1) directly represses CRLF2 transcription through H3K9me3 enrichment at the CRLF2 promoter, and loss of this repression contributes to aberrant CRLF2 expression in leukemia [PMID:27391346].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of CRLF2 as a novel type I cytokine receptor with characteristic structural domains established its membership in the cytokine receptor family and its pseudoautosomal chromosomal location.\",\n      \"evidence\": \"cDNA library screening, Northern blot, and FISH mapping in human tissues\",\n      \"pmids\": [\"11474172\", \"11237741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown at this stage\", \"No signaling pathway activation demonstrated\", \"Physiological function undetermined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that CRLF2 heterodimerizes with IL-7Rα to form the functional TSLP receptor resolved the receptor composition question and linked CRLF2 to TSLP-mediated immune signaling.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, and genomic structure characterization across species\",\n      \"pmids\": [\"11891057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling mechanism downstream of receptor engagement not yet defined\", \"Role of individual intracellular residues unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of P2RY8-CRLF2 and IGH-CRLF2 rearrangements causing overexpression, the F232C gain-of-function mutation causing constitutive dimerization, and cooperation with mutant JAK2 for cytokine-independent transformation established CRLF2 as a central oncogenic scaffold in B-ALL.\",\n      \"evidence\": \"Genomic deletion analysis, Ba/F3 transformation assays, JAK-STAT signaling assays, and primary B-cell progenitor transduction across multiple independent groups\",\n      \"pmids\": [\"19838194\", \"19641190\", \"20018760\", \"19965641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Detailed intracellular signaling requirements not dissected\", \"Whether CRLF2 overexpression alone is sufficient for transformation unclear\", \"In vivo leukemogenesis models not yet established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Systematic mutagenesis established that TSLP signaling through the CRLF2/IL-7Rα complex requires at least one cytoplasmic tyrosine residue in either chain, distinguishing TSLP from IL-7 signaling which depends specifically on IL-7Rα Y449.\",\n      \"evidence\": \"Site-directed mutagenesis of all cytoplasmic tyrosines in both receptor chains with Ba/F3 proliferation readout\",\n      \"pmids\": [\"20144186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of specific signaling molecules recruited to CRLF2 tyrosines not established\", \"Role of box1/box2 motifs not yet systematically tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Domain dissection revealed that CRLF2 box1 and W286 are universally required for signaling, while Y368 is selectively required for F232C-driven but not TSLP- or mutant JAK2-driven signaling, establishing distinct intracellular wiring for different oncogenic contexts; concurrently, primary patient samples demonstrated interconnected JAK/STAT and PI3K/mTOR pathway activation downstream of CRLF2.\",\n      \"evidence\": \"Systematic domain mutagenesis with global quantitative phosphoproteomics in Ba/F3 cells; phospho-flow cytometry with JAK inhibitor treatment in primary CRLF2-rearranged ALL patient samples\",\n      \"pmids\": [\"22915648\", \"22685175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for differential Y368 requirement unknown\", \"Direct kinase-substrate relationships within the PI3K/mTOR branch not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying Ikaros as a direct transcriptional repressor of CRLF2 via H3K9me3 promoter enrichment provided a mechanism explaining how IKZF1 loss-of-function mutations lead to aberrant CRLF2 upregulation in leukemia.\",\n      \"evidence\": \"ChIP assay demonstrating direct Ikaros binding to CRLF2 promoter, CK2 inhibitor treatment modulating Ikaros–CRLF2 promoter interaction\",\n      \"pmids\": [\"27391346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcription factors co-regulate CRLF2 promoter not addressed\", \"Chromatin-level mechanism beyond H3K9me3 not explored\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Single-cell proteomics revealed that CRLF2-driven signaling in primary B-ALL involves coordinated co-activation of JAK/STAT, PI3K, and CREB pathways, and that SRC/ABL inhibition disrupts this network more effectively than JAK or PI3K inhibition alone.\",\n      \"evidence\": \"CyTOF mass cytometry of 15 primary B-ALL patient samples with pharmacological perturbation\",\n      \"pmids\": [\"29796158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical link between CRLF2 and SRC family kinases not demonstrated\", \"Whether CREB activation is direct or indirect unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Quantitative phosphoproteomics of TSLP-stimulated CRLF2-rearranged cells expanded the signaling landscape to include phosphorylation of IGF1R, FGFR1, and Rap1 pathway components, revealing broader receptor cross-talk than previously appreciated.\",\n      \"evidence\": \"SILAC-based phosphotyrosine profiling in CRLF2-rearranged cell lines stimulated with TSLP\",\n      \"pmids\": [\"32801162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IGF1R/FGFR1 phosphorylation is a direct consequence of CRLF2 signaling or a secondary effect not resolved\", \"Functional significance of Rap1 pathway activation in leukemogenesis untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"HMGN1 overexpression was shown to cooperate with P2RY8-CRLF2 to drive cytokine-independent transformation and enhance JAK/STAT signaling, while also promoting P2RY8::CRLF2 fusion formation itself, establishing HMGN1 as both a predisposing and cooperating factor in CRLF2-driven leukemogenesis.\",\n      \"evidence\": \"Ba/F3 transformation assay, CRISPR/Cas9 knockout xenograft model, inducible PAR deletion model with HMGN1 expression\",\n      \"pmids\": [\"34857887\", \"37483494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which HMGN1 promotes preferential repair to form P2RY8::CRLF2 fusion not defined at the molecular level\", \"Whether HMGN1-mediated chromatin changes directly alter CRLF2 locus accessibility unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A genome-wide CRISPR screen revealed that STAT5A/B and STAT3 are largely dispensable for CRLF2-rearranged ALL cell survival, while RAS pathway regulators including CRKL are critical for fitness and ruxolitinib sensitivity, reframing the signaling dependencies of CRLF2-driven leukemia.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 dropout screen with genetic depletion and in vivo drug testing in IgH-CRLF2-rearranged ALL cells\",\n      \"pmids\": [\"34587248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why STAT5 is dispensable despite being prominently phosphorylated is mechanistically unexplained\", \"Whether RAS dependency generalizes to P2RY8-CRLF2 contexts not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CRLF2 overexpression in a Down syndrome B-progenitor model impaired B-cell differentiation and upregulated E2F signaling but was insufficient for transformation, formally demonstrating the requirement for cooperating events.\",\n      \"evidence\": \"Dp16 mouse model with CRLF2 retroviral overexpression, immunophenotyping, and gene expression profiling\",\n      \"pmids\": [\"35306048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which cooperating mutations are minimally sufficient with CRLF2 overexpression for transformation not defined in this model\", \"Relevance of E2F upregulation to leukemogenesis not functionally tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the CRLF2/IL-7Rα/TSLP ternary complex, why STAT5 is dispensable despite robust phosphorylation in CRLF2-rearranged ALL, the identity of direct kinase substrates linking CRLF2 to RAS and PI3K pathway activation, and the minimal cooperating genetic events required for CRLF2-driven leukemic transformation in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of the CRLF2-containing receptor complex\", \"Mechanism of STAT5 dispensability in CRLF2-rearranged ALL unexplained\", \"Minimal cooperating oncogenomic lesion set for CRLF2-driven transformation undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 7, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 10, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [3, 4, 5, 8, 9, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 7, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4, 5, 6, 15]}\n    ],\n    \"complexes\": [\n      \"TSLP receptor (CRLF2/IL-7Rα heterodimer)\"\n    ],\n    \"partners\": [\n      \"IL7R\",\n      \"JAK2\",\n      \"JAK1\",\n      \"STAT5A\",\n      \"STAT5B\",\n      \"IKZF1\",\n      \"HMGN1\",\n      \"CRKL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}